Herantis Pharma announced that it has raised c €6.8m in gross proceeds through the issuance of new shares in a directed share offering. This further strengthens its balance sheet, extending the current cash runway into 2022 and beyond key inflection points for priority assets CDNF in Parkinson’s disease (Phase I/II extension study data expected in Q320) and Lymfactin in breast cancer-associated lymphedema (Phase II top-line data expected in Q121). We increase our valuation of Herantis to €93.6m or €12.4/share, reflecting the additional funds raised through the share offering, while maintaining all other assumptions and forecasts.
Written by
Herantis Pharma |
Directed share offering |
Share offering |
Pharma & biotech |
27 May 2020 |
Share price performance
Business description
Analysts
Herantis Pharma is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||
Herantis Pharma announced that it has raised c €6.8m in gross proceeds through the issuance of new shares in a directed share offering. This further strengthens its balance sheet, extending the current cash runway into 2022 and beyond key inflection points for priority assets CDNF in Parkinson’s disease (Phase I/II extension study data expected in Q320) and Lymfactin in breast cancer-associated lymphedema (Phase II top-line data expected in Q121). We increase our valuation of Herantis to €93.6m or €12.4/share, reflecting the additional funds raised through the share offering, while maintaining all other assumptions and forecasts.
Year end |
Revenue |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/18 |
0.0 |
(4.2) |
(0.8) |
0.0 |
N/A |
N/A |
12/19 |
0.0 |
(8.0) |
(1.4) |
0.0 |
N/A |
N/A |
12/20e |
0.0 |
(5.3) |
(0.7) |
0.0 |
N/A |
N/A |
12/21e |
0.0 |
(5.6) |
(0.7) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Due to strong demand from investors, Herantis confirmed that it has increased the directed share offering to c €6.8m from a planned €5m, through the issue of 875,000 new shares (13% of the previous number of outstanding shares) at a subscription price of €7.8/share.
The additional funding will strengthen Herantis’s balance sheet and extend its cash runway beyond the key inflection points of its lead assets and into 2022. The proceeds will be used to advance its clinical pipeline and complete preparations for potential Phase II and III studies for CDNF and Lymfactin respectively, as well as developing xCDNF, a non-invasive next generation CDNF, which has shown promising results in preclinical studies.
Earlier this month, Herantis announced that Dr Craig Cook will succeed Pekka Simula as CEO from 1 July in a smooth transition with a three-month handover period. Herantis expects minimal impact from COVID-19 in the near term and is well placed to withstand any potential disruption, having almost completed all clinical treatments in its ongoing trials (only one remaining patient to be dosed in the Phase I/II CDNF trial) and a significant cash runway.
|
||||||||||||
|
||||||||||||
Research: Healthcare
Currently, Onxeo is running a triple combination Phase Ib study (n=6; AsiDNA plus carboplatin plus paclitaxel). Top line results should be available by end-2020, subject to the COVID-19 pandemic impact. A major expansion of the R&D programme is the new Phase Ib/II REVOCAN trial. This new study will evaluate AsiDNA’s potentially unique ability to reverse tumour resistance to the PARP inhibitor, niraparib. First data are expected by the end of 2020 or early-2021. The outcomes of these studies will define AsiDNA’s mid- to late-stage development, so they represent substantial catalysts for the share price. Newly released preclinical data suggest that AsiDNA could also abrogate resistance to tyrosine kinase inhibitors (TKIs), which could significantly broaden its applications. Our valuation is €134m or €2.00 per share.